Effective July 1, 2022, Dr. Sriram Venneti, Professor of Pathology, was appointed as Scientific Research Director for the Chad Carr Pediatric Brain Tumor Center (CC-PBTC). Additionally, Dr. Carl Koschmann, Assistant Professor of Pediatrics, was appointed as Clinical Research Director for the CC-PBTC.
In partnership with Packard Health, Michigan Medicine Laboratories, has opened a new laboratory patient service center for specimen collection at Packard Health Main (2650 Carpenter Road, Ann Arbor, MI 48108). The facility houses phlebotomists skilled in caring for patients of all ages and appointments are not needed.
A landmark study into quantitative image analysis in ER, PgR, and HER2 in invasive breast carcinoma was recently published in the American Journal of Clinical Pathology. Dr. Mustafa Yousif, Assistant Professor of Breast Pathology and Informatics, and colleagues conducted a retrospective study of 1,367 invasive breast carcinomas of all histopathology subtypes, for which ER, PgR, and HER2 were analyzed by manual scoring. These were compared to the results obtained using quantitative image analysis (QIA). QIA uses a form of artificial intelligence (AI) called deep learning to identify specific regions of interest and to interpret that based on programmed algorithms.
The role of artificial intelligence (AI) in healthcare continues to expand. In a recent issue of BMC Cancer, Dr. Vipulkumar Dadhania (first author) and colleagues published a result of their study Leveraging artificial intelligence to predict ERG gene fusion status in prostate cancer. The expert team from the Michigan Center for Translational Pathology developed a deep-learning-based model to predict ERG genomic rearrangements in prostatic adenocarcinomas using only H&E-stained digital slides. Their AI models were accurate at 78.6%-79.7%, depending on the magnification, with a 20x magnification the most accurate. Sensitivity was found to be at 75% across magnification levels (10x, 20x, 40x) and specificity ranged from 81.7% (10x and 40x) to 83.1% (20x).
Drs. Liron Pantanowitz, Jeffrey Myers, Priya Kunju, as well as David and Elle Chapel were featured in the April 2022 edition of CAP Today Magazine, a medical science publication by the College of American Pathologists. The article focuses on the development of the AP hospitalist role at Michigan Medicine.
This month marked the 11th United States and Canadian Academy of Pathology (USCAP)'s Annual Meeting. This year's hybrid-style event was held both in-person and virtually in Los Angeles, California from March 18-24, 2022. The symposium featured several short and long courses, as well evening specialty conferences and ticketed seminars. The conference also included numerous poster sessions, live Q&A segments, and a multitude of social events. Michigan Medicine's Department of Pathology shined as several of our faculty, residents and fellows participated heavily in this year's meeting. Let's take a moment to reflect on some of the top moments from #USCAP2022.
Michigan Medicine Laboratories will be exhibiting at USCAP this month. The 11th annual meeting runs from March 19-24, 2022 in Los Angeles, CA. Be sure to stop by booth 633 and grab a go blue football!
Leadership is not about titles, positions, or flowcharts. It is about one life influencing another,” John Maxwell.
In early 2020, the truth of this statement came to life in the Department of Pathology. Our country, our world, was faced with a pandemic caused by a novel virus for which no hard and fast answers were to be had. In the face of constantly changing “facts,” leadership in Pathology was found at all levels. It began with the Chair, Dr. Charles Parkos.
The West Ann Arbor Blood Draw center located at 380 Parkland Plaza, Suite 130, Ann Arbor, MI 48103 will be closing early at 5:00pm on Wednesday, February 2nd and Thursday, February 3rd. For more information about the blood draw site, please visit West Ann Arbor Health Center | MLabs (umich.edu)
MLabs now offers new approved therapy with KEYTRUDA through the PD-L1 (22C3 Assay). KEYTRUDA is a medicine that may treat certain cancers by working with your immune system. This FDA approved companion diagnostic for KEYTRUDA to evaluate triple-negative breast cancer patients.